These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 25502629

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
    Chen H, Lin C, Peng T, Hu C, Lu C, Li L, Wang Y, Han R, Feng M, Sun F, He Y.
    Cell Death Dis; 2020 Feb 10; 11(2):111. PubMed ID: 32041944
    [Abstract] [Full Text] [Related]

  • 3. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
    Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H.
    Cancer Chemother Pharmacol; 2014 Nov 10; 74(5):1023-8. PubMed ID: 25205428
    [Abstract] [Full Text] [Related]

  • 4. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H.
    Cancer Lett; 2014 Sep 01; 351(2):215-21. PubMed ID: 24887559
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y, Kurasawa M, Yorozu K, Puig O, Bordogna W, Harada N.
    Cancer Chemother Pharmacol; 2016 Mar 01; 77(3):623-8. PubMed ID: 26849637
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, Ninomiya T, Ninomiya K, Oda N, Yoshioka H, Ichikawa H, Inoue M, Takata I, Shibayama T, Kuyama S, Sugimoto K, Harada D, Harita S, Sendo T, Tanimoto M, Kiura K.
    Clin Lung Cancer; 2016 Nov 01; 17(6):602-605. PubMed ID: 27405684
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A.
    Expert Rev Clin Pharmacol; 2016 Aug 01; 9(8):1005-13. PubMed ID: 27232673
    [Abstract] [Full Text] [Related]

  • 12. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S.
    Clin Cancer Res; 2012 Jul 01; 18(13):3592-602. PubMed ID: 22553343
    [Abstract] [Full Text] [Related]

  • 13. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 01; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 14. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.
    Tanimoto A, Yamada T, Nanjo S, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S.
    Oncotarget; 2014 Jul 15; 5(13):4920-8. PubMed ID: 24952482
    [Abstract] [Full Text] [Related]

  • 15. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G, Seto T.
    Respir Investig; 2014 Nov 15; 52(6):330-8. PubMed ID: 25453376
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
    Dong X, Fernandez-Salas E, Li E, Wang S.
    Neoplasia; 2016 Mar 15; 18(3):162-71. PubMed ID: 26992917
    [Abstract] [Full Text] [Related]

  • 18. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH, Klempner SJ, Greenbowe JR, Azada M, Schrock AB, Ali SM, Ross JS, Stephens PJ, Miller VA.
    J Thorac Oncol; 2014 Dec 15; 9(12):1821-5. PubMed ID: 25393796
    [Abstract] [Full Text] [Related]

  • 19. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
    Santarpia M, Altavilla G, Rosell R.
    Expert Rev Respir Med; 2015 Jun 15; 9(3):255-68. PubMed ID: 25652176
    [Abstract] [Full Text] [Related]

  • 20. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.
    Lancet; 2017 Jul 01; 390(10089):29-39. PubMed ID: 28501140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.